Caris Life Sciences Links AI to Longer Survival in Pancreatic Cancer
Irving, Texas, United States, Aug 27, 2026 Caris Life Sciences has announced the publication of a study in npj...
Caris Life Sciences
Advertisement
Skyhawk Therapeutics Advances Global Phase 2/3 HD Trial
BOSTON, Mass. — July 14, 2026 Skyhawk Therapeutics, Inc. has announced a major expansion of its global pivotal Phase...
Caris Life Sciences Expands PTEN Testing for Prostate Cancer
IRVING, Texas — July 14, 2026 Caris Life Sciences has expanded its precision oncology portfolio with the launch of...
Caris Lookback Program Expands Precision Oncology Access
IRVING, Texas, May 15, 2026 Caris Life Sciences announced the publication of a new study in The Oncologist demonstrating...
Caris Life Sciences Shows WES Improves Immunotherapy Survival Prediction
IRVING, Texas, May 11, 2026 Caris Life Sciences announced the publication of a new study in Cancer Immunology, Immunotherapy...
Advertisements
Caris Life Sciences Files NY Approval for Caris Assure
IRVING, Texas, May 8, 2026 Caris Life Sciences® has submitted an application to the New York State Department of...
Caris Life Sciences Gains MolDX Approval for ChromoSeq
IRVING, Texas – May 4, 2026 Caris Life Sciences has secured MolDX approval for its flagship Caris ChromoSeq™ assay,...
Caris Launches ChromoSeq for Myeloid Cancer Profiling
IRVING, Texas, USA — April 1, 2026 Caris Life Sciences® has announced the launch of Caris ChromoSeq™, the world’s...
Caris Detect Study Shows Strong Early Cancer Detection
IRVING, Texas, USA, March 31, 2026 Caris Life Sciences has announced final results from the Achieve 1 study, demonstrating...
Caris Detect Achieves 99% Specificity in MCED
IRVING, Texas, February 26, 2026 Caris Life Sciences® (NASDAQ: CAI) announced an interim readout from its Achieve 1 clinical...
Advertisement
